Update on GMDN Governance

21 March 2023
MHRA and ANVISA representatives have joined the Authorities Strategic Advisory Group (ASAG) committee, which represents medical device regulators that use the GMDN.
Earlier in 2022, the GMDN Trustees established the ASAG committee.
The ASAG’s key role is to provide advice and feedback to Trustees and the GMDN Agency, including:- Having appropriate review structures in place to ensure that relevant stakeholders, including from different regions, can provide feedback and be consulted about the GMDN supporting their needs.
- The promotion of the GMDN to encourage broader adoption and global harmonisation of the GMDN as a detailed nomenclature that underpins an efficient and effective regulatory model of safety and performance for medical devices.
- Enhancing medical device safety by use of the GMDN that facilitates and promotes data exchange and analysis.
Recent Posts
- GMDN FOCUS – March 2025 March 31, 2025
- Global Medical Device Nomenclature (GMDN): A valuable tool for the development of National Essential Diagnostics Lists (NEDLs) March 25, 2025
- GMDN Agency joins Joint Initiative Council to advance global health informatics March 4, 2025
- GMDN FOCUS – February 2025 February 28, 2025
- Shaping Our Future: Insights and Actions from the GMDN Agency’s 2024 Annual Survey February 27, 2025